Radiation Therapy for Breast Cancer
(PRATO Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are undergoing treatment for a severe autoimmune disease, you may not be eligible to participate.
What data supports the effectiveness of the treatment Radiation Therapy for Breast Cancer?
Research shows that shorter courses of radiation therapy, like those lasting 3-4 weeks, are generally as effective as longer ones for early breast cancer, reducing local recurrence and mortality. Additionally, accelerated treatments focusing on the tumor bed have been evaluated for their potential to reduce treatment time while maintaining effectiveness.12345
Is radiation therapy for breast cancer safe?
How does the 1-2 week radiation therapy for breast cancer differ from other treatments?
What is the purpose of this trial?
This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a "concomitant boost"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.
Research Team
Silvia C. Formenti, MD
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for individuals with early breast cancer. Participants should be suitable for radiation therapy and have no prior treatment that would interfere with the study. Specific details about who can or cannot join are not provided here.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 2600 cGy in 5 fractions over one week or 3200 cGy in 10 fractions with a concomitant tumor bed boost over two weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, including evaluations of fibrosis, local control, and breast cosmesis
Long-term follow-up
Participants are monitored for long-term outcomes such as local control and fibrosis at 5 and 10 years
Treatment Details
Interventions
- Radiation therapy - 1 week
- Radiation therapy - 2 weeks
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor